The Inhibitory Activities of the Edible Green Alga Capsosiphon Fulvescens on Rat Lens Aldose Reductase and Advanced Glycation End Products Formation

Overview

Journal Eur J Nutr

Specialty Nutritional Sciences

Date 2013 Apr 12

PMID 23575770

Citations 11

Authors

Md Nurul Islam

Sung Hwa Choi

Hye Eun Moon

Jin Ju Park

Hyun Ah Jung

Mi Hee Woo

Hee Chul Woo

Jae Sue Choi

Affiliations

Soon will be listed here.

Abstract

Purpose: Accumulating evidence suggests that inhibitors of aldose reductase (AR) may prevent hyperglycemia-induced long-term complications in diabetes mellitus. In the present study, we evaluated the AR inhibitory potential of ethanolic (EtOH) extracts from 22 seaweed species.

Methods: AR inhibitory activities of the selected seaweed species were evaluated using the rat lens aldose reductase (RLAR) inhibitory assay.

Results: All extracts exhibited RLAR inhibitory activity, which ranged from 5.87 to 92.71 % at a concentration of 50 μg/mL. Since Capsosiphon fulvescens exhibited significant inhibitory potential and is a frequently used foodstuff, it was selected for a detailed investigation using RLAR and advanced glycation end products (AGE) formation inhibitory assays. Among the different solvent-soluble fractions, the CH2Cl2, EtOAc, and n-BuOH fractions showed promising RLAR and AGE formation inhibitory activities. Considering the AR inhibitory potential, CH2Cl2 and EtOAc fractions were selected for chromatographic separation and yielded 11 compounds in which capsofulvesin A, capsofulvesin B, and chalinasterol showed potential RLAR inhibitory activity with the respective IC50 values of 52.53, 101.92, and 345.27 μM. Kinetic studies revealed that capsofulvesin A and chalinasterol exhibited mixed type inhibition, while capsofulvesin B exhibited noncompetitive inhibition. To our knowledge, this is the first report of AR inhibitory activity of the glycolipids capsofulvesin A and capsofulvesin B.

Conclusions: Our results clearly indicate the potential RLAR and AGE formation inhibitory activities of C. fulvescens as well as its isolated constituents, which could be further explored to develop therapeutic modalities for the treatment of diabetes and related complications.

Citing Articles

Revolutionizing Diabetes Care: The Role of Marine Bioactive Compounds and Microorganisms.

Reddy K, Rakesh K, Prathyusha S, Gupta J, Nagasree K, Lokeshvar R Cell Biochem Biophys. 2024; 83(1):193-213.

PMID: 39254792 DOI: 10.1007/s12013-024-01508-1.

Extraction, Isolation and Biological Activity of Two Glycolipids from .

Sun Y, Mu Y, Li T, Wang S, Li Y, Liu J Mar Drugs. 2024; 22(4).

PMID: 38667761 PMC: 11051132. DOI: 10.3390/md22040144.

Uses of Papaya Leaf and Seaweed Supplementations for Controlling Glucose Homeostasis in Diabetes.

Nyakundi B, Yang J Int J Mol Sci. 2023; 24(7).

PMID: 37047820 PMC: 10095424. DOI: 10.3390/ijms24076846.

Bioactivities of Lipid Extracts and Complex Lipids from Seaweeds: Current Knowledge and Future Prospects.

Lopes D, Rey F, Leal M, Lillebo A, Calado R, Domingues M Mar Drugs. 2021; 19(12).

PMID: 34940685 PMC: 8708724. DOI: 10.3390/md19120686.

Cataract Preventive Role of Isolated Phytoconstituents: Findings from a Decade of Research.

Lim V, Schneider E, Wu H, Pang I Nutrients. 2018; 10(11).

PMID: 30373159 PMC: 6265913. DOI: 10.3390/nu10111580.

References

McCune L, Johns T . Antioxidant activity in medicinal plants associated with the symptoms of diabetes mellitus used by the indigenous peoples of the North American boreal forest. J Ethnopharmacol. 2002; 82(2-3):197-205. DOI: 10.1016/s0378-8741(02)00180-0. View

Fang Z, Jeong S, Jung H, Choi J, Min B, Woo M . Capsofulvesins A-C, cholinesterase inhibitors from Capsosiphon fulvescens. Chem Pharm Bull (Tokyo). 2012; 60(11):1351-8. DOI: 10.1248/cpb.c12-00268. View

Wada R, Yagihashi S . Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005; 1043:598-604. DOI: 10.1196/annals.1338.067. View

Cheng A, Fantus I . Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005; 172(2):213-26. PMC: 543986. DOI: 10.1503/cmaj.1031414. View

Bucala R, Cerami A . Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992; 23:1-34. DOI: 10.1016/s1054-3589(08)60961-8. View

Resnick H, Foster G, Bardsley J, Ratner R . Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006; 29(3):531-7. DOI: 10.2337/diacare.29.03.06.dc05-1254. View

Kato A, Yasuko H, Goto H, Hollinshead J, Nash R, Adachi I . Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity. Phytomedicine. 2007; 16(2-3):258-61. DOI: 10.1016/j.phymed.2007.04.008. View

Wang W, Okada Y, Shi H, Wang Y, Okuyama T . Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula. J Nat Prod. 2005; 68(4):620-2. DOI: 10.1021/np040199j. View

Lee J, Kim N, Nam J, Lee Y, Jang D, Kim Y . Scopoletin from the flower buds of Magnolia fargesii inhibits protein glycation, aldose reductase, and cataractogenesis ex vivo. Arch Pharm Res. 2010; 33(9):1317-23. DOI: 10.1007/s12272-010-0904-z. View

10.

Dunlop M . Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl. 2000; 77:S3-12. DOI: 10.1046/j.1523-1755.2000.07702.x. View

11.

Fujisawa T, Ikegami H, Inoue K, Kawabata Y, Ogihara T . Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism. 2005; 54(3):387-90. DOI: 10.1016/j.metabol.2004.10.004. View

12.

Wautier J, Guillausseau P . Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001; 27(5 Pt 1):535-42. View

13.

Hiroyuki F, Tomohide Y, Kazunori O . Efficacy and safety of Touchi extract, an alpha-glucosidase inhibitor derived from fermented soybeans, in non-insulin-dependent diabetic mellitus. J Nutr Biochem. 2001; 12(6):351-356. DOI: 10.1016/s0955-2863(01)00149-8. View

14.

Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Simorini F, Novellino E . Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives. J Med Chem. 2003; 46(8):1419-28. DOI: 10.1021/jm030762f. View

15.

Suryanarayana P, Anil Kumar P, Saraswat M, Petrash J, Reddy G . Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. Mol Vis. 2004; 10:148-54. View

16.

Moon H, Islam N, Ahn B, Chowdhury S, Sohn H, Jung H . Protein tyrosine phosphatase 1B and α-glucosidase inhibitory Phlorotannins from edible brown algae, Ecklonia stolonifera and Eisenia bicyclis. Biosci Biotechnol Biochem. 2011; 75(8):1472-80. DOI: 10.1271/bbb.110137. View

17.

Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S . Advanced glycation end products in clinical nephrology. Kidney Blood Press Res. 2003; 27(1):18-28. DOI: 10.1159/000075533. View

18.

Nathan D . Long-term complications of diabetes mellitus. N Engl J Med. 1993; 328(23):1676-85. DOI: 10.1056/NEJM199306103282306. View

19.

Thomas M, Baynes J, Thorpe S, Cooper M . The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005; 6(4):453-74. DOI: 10.2174/1389450054021873. View

20.

Suen C, Burn P . The potential of incretin-based therapies in type 1 diabetes. Drug Discov Today. 2011; 17(1-2):89-95. DOI: 10.1016/j.drudis.2011.08.017. View